The company was established in Asia in Israel. The leading representative office of defined VC is situated in the Tel Aviv.
The fund has specific favorite in a number of founders of portfolio startups. For fund there is no match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight HiFiBiO, Cygnus Biosciences, Soluto. Among the most successful fund investment fields, there are Advertising, Health Care. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The common things for fund are deals in the range of 5 - 10 millions dollars. Speaking about the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2013. Comparing to the other companies, this Proxima Ventures Ltd performs on 19 percentage points less the average number of lead investments.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Proxima Ventures Ltd, startups are often financed by Founder Collective, Yueyin Venture Capital, Nest.Bio Ventures. The meaningful sponsors for the fund in investment in the same round are Yueyin Venture Capital, Giza Venture Capital, Founder Collective. In the next rounds fund is usually obtained by Giza Venture Capital, Bessemer Venture Partners, initial.vc.
The fund was created by Chaim Venezia, Uri Ra'anan, Zvi Margalit. Besides them, we counted 4 critical employees of this fund in our database.
Related Funds
Funds with similar focus
Fund Name | Location |
AI Music | England, Kent, United Kingdom |
Brockhaus Private Equity | Frankfurt, Germany, Hessen |
Caton Technology (Asia) | China, Hong Kong, Hong Kong Island |
Fibrotic Ventures | Atlanta, Georgia, United States |
Honest Ventures | - |
MCI Capital SA | Mazowieckie, Poland, Warsaw |
NEC Capital Solutions | Chiyoda, Japan |
Optim | Japan, Tokyo |
Purity Star | - |
SGRF | Masqat, Muscat, Oman |
Sniper Investments | Belgium, Limburg, Mechelen-bovelingen |
Sumin Investment | - |
The Raine Group | New York, New York, United States |
Topspin Fund | - |
Weatherford International | Baar, Switzerland, Zug |
Zero2IPO Capital | Beijing, Beijing, China |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
VerImmune | $4M | 23 Sep 2024 | Baltimore, Maryland, United States | ||
Rapafusyn Pharmaceuticals | $28M | 20 Jun 2024 | Baltimore, Maryland, United States | ||
VerImmune | $3M | 20 Sep 2023 | Baltimore, Maryland, United States | ||
Immune-Onc Therapeutics | $25M | 05 Jan 2023 | Palo Alto, California, United States | ||
VerImmune | $2M | 27 Jul 2022 | Baltimore, Maryland, United States | ||
Yidianling | $30M | 22 Dec 2021 | Shanghai, China | ||
Great Bay Bio | $10M | 01 Dec 2021 | Hong Kong Island, Hong Kong, China | ||
Bioelectronica | 08 Feb 2021 | Reno, Nevada, United States | |||
Singlera Genomics | $150M | 15 Dec 2020 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
VerImmune | $4M | 23 Sep 2024 | Baltimore, Maryland, United States | ||
Rapafusyn Pharmaceuticals | $28M | 20 Jun 2024 | Baltimore, Maryland, United States | ||
VerImmune | $3M | 20 Sep 2023 | Baltimore, Maryland, United States | ||
Immune-Onc Therapeutics | $25M | 05 Jan 2023 | Palo Alto, California, United States | ||
VerImmune | $2M | 27 Jul 2022 | Baltimore, Maryland, United States | ||
Yidianling | $30M | 22 Dec 2021 | Shanghai, China | ||
Great Bay Bio | $10M | 01 Dec 2021 | Hong Kong Island, Hong Kong, China | ||
Bioelectronica | 08 Feb 2021 | Reno, Nevada, United States | |||
Singlera Genomics | $150M | 15 Dec 2020 | San Diego, California, United States |